Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors

A compound of general formula (I)

• wherein:
• R1 is selected from the group consisting of phenyl, 6-membered heteroaryl, phenoxy, and 6:
• membered heteroaryloxy;
• wherein the phenyl, 6-membered heteroaryl, phenoxy, or 6-membered heteroaryloxy is optionally substituted with one or more substituents independently selected from R3;
• R2 is selected from the group consisting of (C3-C7)cycloalkyl, bridged (C3-C7)cycloalkyl, and (4-7 membered) heterocycloalkyl;
• wherein the (C3-C7)cycloalkyl, bridged (C3-C7)cycloalkyl, or (4-7 membered) heterocycloalkyl is all of which are optionally substituted with one or more substituents independently selected from R4;
• R3 is selected from the group consisting of halogen, —CN, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, and (C3-C6)cycloalkyl;
• R4 is selected from the group consisting of fluoro, —CN, —OH, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, —ORx, —S(O)2Rx, —S(O)2NRaRb, —C(O)Rx, —C(O)(ORx), and —C(O)NRaRb;
• Rx is selected from the group consisting of (C1-C4)alkyl and (C3-C6)cycloalkyl;
• Ra and Rb are each independently selected from the group consisting of hydrogen, (C1-C4)alkyl, and (C3-C6)cycloalkyl;
• and
• S* is a chiral sulfur atom with (R) stereochemistry;
• or a pharmaceutically acceptable salt, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, hydrate or solvates thereof.